Published in Eur J Immunol on April 01, 2012
The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol (Oxf) (2014) 0.79
Altered manifestations of skin disease at sites affected by neurological deficit. Br J Dermatol (2015) 0.78
Nerve-derived transmitters including peptides influence cutaneous immunology. Brain Behav Immun (2013) 0.77
Calcitonin Gene-Related Peptide-Exposed Endothelial Cells Bias Antigen Presentation to CD4+ T Cells toward a Th17 Response. J Immunol (2016) 0.75
Pituitary Adenylate Cyclase-Activating Polypeptide Is Upregulated in Murine Skin Inflammation and Mediates Transient Receptor Potential Vanilloid-1-Induced Neurogenic Edema. J Invest Dermatol (2015) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
Simultaneous inference in general parametric models. Biom J (2008) 23.64
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2006) 13.75
Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol (2007) 12.72
Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science (1990) 12.13
IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol (2007) 10.71
The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 10.55
IL-22 increases the innate immunity of tissues. Immunity (2004) 8.30
Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol (1989) 5.92
Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system. Proc Natl Acad Sci U S A (1992) 5.55
Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol (2009) 4.73
Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol (2009) 4.69
IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol (2005) 4.49
Th17 cells in human disease. Immunol Rev (2008) 4.27
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol (2008) 4.18
IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest (2008) 4.12
Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest (2009) 4.10
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med (2007) 3.68
Epidermal Langerhans cells bear Fc and C3 receptors. Nature (1977) 3.21
Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol (2008) 3.19
The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol (2007) 3.06
Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A (1989) 2.87
IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol (2009) 2.77
Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev (2006) 2.73
Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol (2000) 2.66
Cultured human Langerhans cells resemble lymphoid dendritic cells in phenotype and function. J Invest Dermatol (1989) 2.63
Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses. Immunity (2011) 2.58
Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol (2009) 2.46
In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol (2006) 2.44
Protumor vs antitumor functions of IL-17. J Immunol (2009) 2.38
IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol (1999) 2.29
Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol (2008) 2.19
A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol (2007) 2.16
Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol (2009) 1.94
Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature (1993) 1.90
The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev (2000) 1.71
Precarious balance: Th17 cells in host defense. Infect Immun (2009) 1.60
Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci U S A (2009) 1.44
Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther (2009) 1.44
IL-7 promotes T cell proliferation through destabilization of p27Kip1. J Exp Med (2006) 1.40
Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin (2005) 1.36
IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int Immunopharmacol (2004) 1.35
Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol (2009) 1.33
Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. J Invest Dermatol (2006) 1.33
From skin dendritic cells to a simplified classification of human and mouse dendritic cell subsets. Eur J Immunol (2010) 1.29
TLR2-activated human langerhans cells promote Th17 polarization via IL-1beta, TGF-beta and IL-23. Eur J Immunol (2009) 1.28
VPAC receptors for VIP and PACAP. Receptors Channels (2002) 1.28
Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. Regul Pept (2002) 1.23
Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother (2010) 1.21
Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm (2009) 1.17
Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice. Br J Dermatol (2011) 1.17
Human Langerhans cells capture measles virus through Langerin and present viral antigens to CD4⁺ T cells but are incapable of cross-presentation. Eur J Immunol (2011) 1.14
Regulation of interleukin-12 signalling during T helper phenotype development. Adv Exp Med Biol (1996) 1.13
An update of the defensive barrier function of skin. Yonsei Med J (2006) 1.11
Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol (1991) 1.10
Calcitonin gene-related peptide biases Langerhans cells toward Th2-type immunity. J Immunol (2008) 1.09
The role of cutaneous sensory nerves in the maintenance of psoriasis. Int J Dermatol (1990) 1.07
Steady state migratory RelB+ langerin+ dermal dendritic cells mediate peripheral induction of antigen-specific CD4+ CD25+ Foxp3+ regulatory T cells. Eur J Immunol (2011) 1.03
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol (1999) 1.02
Cystic fibrosis, vasoactive intestinal polypeptide, and active cutaneous vasodilation. J Appl Physiol (1985) (1990) 0.98
Stress and atopic dermatitis. Curr Allergy Asthma Rep (2008) 0.97
Cytokine mediators of Th17 function. Eur J Immunol (2009) 0.97
Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide: relevance to functional effects. Proc Natl Acad Sci U S A (1995) 0.95
Down-regulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis. J Allergy Clin Immunol (2003) 0.94
CGRP, PACAP, and VIP modulate Langerhans cell function by inhibiting NF-kappaB activation. J Invest Dermatol (2007) 0.93
Translational mini-review series on Th17 cells: are T helper 17 cells really pathogenic in autoimmunity? Clin Exp Immunol (2009) 0.93
Langerhans cells: antigen presenting cells of the epidermis. Immunobiology (1984) 0.92
Immunohistochemical detection of human skin nerve fibers. Acta Histochem (1997) 0.91
Inhibition of the induction of delayed-type and contact hypersensitivity by calcitonin gene-related peptide. J Immunol (1995) 0.91
Stress and the skin. G Ital Dermatol Venereol (2010) 0.88
Quantitative histochemical analysis of mast cells and sensory nerves in psoriatic skin. J Pathol (1996) 0.87
Remission of psoriasis associated with cutaneous nerve section. Arch Dermatol (1971) 0.87
The role of dendritic cells in cutaneous immunity. Arch Dermatol Res (1996) 0.85
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression. J Immunol (2000) 0.85
Vasoactive intestinal peptide modulates Langerhans cell immune function. J Immunol (2004) 0.85
VIP and PACAP. Results Probl Cell Differ (2010) 0.83
Substance P is diminished and vasoactive intestinal peptide is augmented in psoriatic lesions and these peptides exert disparate effects on the proliferation of cultured human keratinocytes. J Invest Dermatol (1992) 0.81
Pituitary adenylate cyclase-activating polypeptide inhibits cutaneous immune function. Eur J Immunol (2003) 0.81
Serum levels of vasoactive intestinal peptide are elevated in patients with atopic dermatitis. J Dermatol Sci (2003) 0.80
Pituitary adenylate cyclase-activating polypeptide and islet amyloid polypeptide in primary sensory neurons: functional implications from plasticity in expression on nerve injury and inflammation. Mol Neurobiol (1999) 0.79
Digital denervation associated with absence of nail and distal interphalangeal joint involvement in psoriatic arthritis. J Rheumatol (1995) 0.78
[Basal concentration of Substance P (SP) and Vasoactive Intestinal Peptide (VIP) in the blood serum of children with allergic dermatitis]. Med Wieku Rozwoj (2003) 0.76
Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem (2003) 5.40
Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res (2006) 2.96
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther (2005) 2.85
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology (2002) 2.72
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab (2006) 2.64
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos (2007) 2.17
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis (2012) 1.91
Retinoids regulate stem cell differentiation. J Cell Physiol (2011) 1.91
ATPgammaS enhances the production of inflammatory mediators by a human dermal endothelial cell line via purinergic receptor signaling. J Invest Dermatol (2006) 1.76
[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A (2007) 1.73
Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med (2012) 1.71
Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer (2014) 1.71
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res (2006) 1.71
MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol (2008) 1.60
Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. J Clin Pharmacol (2006) 1.56
Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol (2009) 1.51
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol (2007) 1.51
A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol (2003) 1.46
Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res (2005) 1.44
Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis (2009) 1.43
Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J Immunol (2007) 1.42
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother (2008) 1.41
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol (2008) 1.40
Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone. Cardiovasc Ther (2009) 1.40
Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol (2011) 1.38
Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One (2011) 1.29
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother (2009) 1.24
Distinct specificities of Mycobacterium tuberculosis and mammalian proteasomes for N-acetyl tripeptide substrates. J Biol Chem (2008) 1.23
Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol (2010) 1.22
Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis (2008) 1.21
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol (2006) 1.19
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res (2011) 1.18
Opening up to precompetitive collaboration. Sci Transl Med (2010) 1.18
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother (2008) 1.16
Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells. J Virol (2006) 1.14
Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother (2008) 1.11
Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin Cancer Res (2006) 1.09
Calcitonin gene-related peptide biases Langerhans cells toward Th2-type immunity. J Immunol (2008) 1.09
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol (2009) 1.07
Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol Ther (2002) 1.06
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab (2007) 1.04
Catecholamines inhibit the antigen-presenting capability of epidermal Langerhans cells. J Immunol (2002) 1.04
A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nat Rev Drug Discov (2006) 1.03
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother (2009) 1.02
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos (2007) 1.01
Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. AAPS J (2008) 0.99
MicroRNA expression aids the preoperative diagnosis of pancreatic ductal adenocarcinoma. Pancreas (2012) 0.98
Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res (2009) 0.97
Augmentation of cutaneous immune responses by ATP gamma S: purinergic agonists define a novel class of immunologic adjuvants. J Immunol (2005) 0.97
Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother (2009) 0.95
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. Br J Clin Pharmacol (2011) 0.94
Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol (2008) 0.94
CGRP, PACAP, and VIP modulate Langerhans cell function by inhibiting NF-kappaB activation. J Invest Dermatol (2007) 0.93
Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J Clin Pharmacol (2010) 0.93
Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res (2005) 0.92
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol (2013) 0.92
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol (2013) 0.91
A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol (2009) 0.90
A pharmacokinetic comparison of adult and paediatric formulations of raltegravir in healthy adults. Antivir Ther (2014) 0.90
Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. Br J Clin Pharmacol (2011) 0.89
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers. J Clin Pharmacol (2008) 0.89
A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology. Anal Biochem (2007) 0.88
Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J Invest Dermatol (2003) 0.88
Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol (2008) 0.88
Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop. Clin Cancer Res (2012) 0.88
Norepinephrine modulates human dendritic cell activation by altering cytokine release. Exp Dermatol (2008) 0.88
Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol (2009) 0.88
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest (2015) 0.88
UVR exposure sensitizes keratinocytes to DNA adduct formation. Cancer Prev Res (Phila) (2009) 0.88
Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients. J Clin Pharmacol (2011) 0.88
Dietary lutein reduces ultraviolet radiation-induced inflammation and immunosuppression. J Invest Dermatol (2004) 0.87
"Soluble" adenylyl cyclase-generated cyclic adenosine monophosphate promotes fast migration in PC12 cells. J Neurosci Res (2008) 0.87
Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma. Arch Pathol Lab Med (2008) 0.87
UV radiation inhibits 15-hydroxyprostaglandin dehydrogenase levels in human skin: evidence of transcriptional suppression. Cancer Prev Res (Phila) (2010) 0.87
MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans. Circ Arrhythm Electrophysiol (2012) 0.86
Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol (2009) 0.86
Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry. Rapid Commun Mass Spectrom (2013) 0.86
A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res (2009) 0.86
Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. AAPS J (2011) 0.85
Vasoactive intestinal peptide modulates Langerhans cell immune function. J Immunol (2004) 0.85
Tetracycline suppresses ATP gamma S-induced CXCL8 and CXCL1 production by the human dermal microvascular endothelial cell-1 (HMEC-1) cell line and primary human dermal microvascular endothelial cells. Exp Dermatol (2008) 0.84
Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol (2006) 0.84
Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor. AAPS J (2011) 0.84
Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther (2014) 0.84
Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J Clin Pharmacol (2010) 0.83
Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos (2009) 0.83
Polypodium leucotomos inhibits ultraviolet B radiation-induced immunosuppression. Photodermatol Photoimmunol Photomed (2008) 0.83
Neuroendocrine regulation of skin dendritic cells. Ann N Y Acad Sci (2006) 0.83
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol (2007) 0.83